Tandem Diabetes: Clinical Win & Rate Cut Rally
Update: 2025-09-18
Description
Tandem Diabetes stock surged 5% on positive clinical data for its Control-IQ Plus system in adults with type 2 diabetes, boosted further by the first Federal Reserve interest rate cut in years. While this offers a glimmer of hope, the stock's high volatility and a year-to-date drop of 64% means investors remain cautiously optimistic, especially amidst the dominance of the AI trade in the market.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
